ANIP

ANI Pharmaceuticals, Inc.

Fundamental data last updated:August 24, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

 


Analyze ANIP on TradingView

VALUATION

P/E

18.92

Market Cap ($M USD)

$1.84B

Forward P/E

5.33

PEG

0.02

PRICE TO SALES

2.00

PRICE TO BOOK

3.02

EV / EBITDA

7.85

5-Year Average P/E

Free Cash Flow Yield

8.98%

DCF Value

$1072.84

Graham Number

$50.93

Price to FCF

11.14

EV to FCF

11.24

Earnings Yield

5.29%

FCF Yield

8.98%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.84%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$4.29

Next Year EPS Growth Estimate

$15.21

Next Year Revenue Growth Estimate

$1.57B

Return on Equity (ROE)

17.32%

FREE CASH FLOW

Operating Margin

13.38%

Debt-to-Equity

0.60

Piotroski F-Score

7

Altman Z-Score

2.72

Return on Invested Capital (ROIC)

10.45%

Current Ratio

3.12

Quick Ratio

2.52

Net Debt to EBITDA

0.07

Interest Coverage

3.86

Gross Profit margin

65.94%

FCF PER SHARE

$7.92

REVENUE PER SHARE

$44.17

Analyze ANIP on TradingView

Gainseekers Quantitative Analysis

Summary

ANIP Pharmaceuticals appears to be a compelling deep value play. Recent pricing indicated it traded significantly below its DCF value, suggesting a market mispricing. The Forward P/E of 5.34 and a robust Earnings Yield highlight potential undervaluation, while an Altman Z-score of 2.75 suggests moderate financial safety. Despite a high Price/Book ratio, the company’s growth prospects and financial health seem solid, positioning it as an attractive opportunity for value investors.

AI Exposure / Tech Reliance

Operating in the healthcare sector, ANIP is well-positioned to leverage AI advancements in drug manufacturing and specialty generics. The industry's inherent need for innovation and efficiency aligns with AI-driven solutions. This adaptability could enhance their competitive edge and operational efficiency.

The Bull Case

For the value-driven investor, ANIP offers a tantalizing proposition. With a strong ROIC of 10.47% and a Piotroski F-Score of 7, the company demonstrates efficient capital allocation and financial health. Its Free Cash Flow Yield of 9.22% and solid operating margins underscore its pricing power and ability to generate cash. These metrics paint a picture of a company with robust fundamentals and growth potential.

The Bear Case

Despite its strengths, ANIP is not without risks. The Price/Book ratio of 3.04 and Price/Sales of 2.02 suggest it may be overvalued relative to its book and sales values. Additionally, the stock's proximity to its 52-week high could indicate technical overextension. Investors should be cautious of these valuation concerns, even as they acknowledge the company's low debt levels and strong growth prospects.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$124.00

Institutional Ownership %

1-Year Beta

0.46

Insider Buying % (6 Mo)

Distance to 52-Week High

22.67%

Distance to 52-Week Low

29.17%

EARNINGS SURPRISE %

60.16%

50-DAY SMA

$78.77

200-DAY SMA

$83.88

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.